Keyword: Tianjin CanSino

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.

CanSino licenses an mRNA coronavirus vaccine. WuXi Biologics set to build $60 million U.S. facility. A Fujifilm drug reportedly fails in COVID-19.

China-based biotech Sinovac will build a new vaccine production facility with the Chinese government's support in the hunt for a COVID-19 shot.

A lack of patients stopped two remdesivir trials in China. FDA cleared Lupin, Dr. Reddy’s and Biocon sites. CanSino's COVID-19 vax moves into phase 2.

CanSino said it's moving its recombinant vaccine into phase 2 "[b]ased on the preliminary safety data of the phase 1 clinical trial.”

Biogen and Bayer deal with coronavirus rule-breakers in China. AbbVie's Kaletra fails COVID-19 study. Fosun licenses BioNTech's coronavirus vaccine.

CanSino and its partners won a go-ahead to move a recombinant coronavirus vaccine into phase 1 testing in Wuhan, China, once the outbreak's center.

Eisai's stock plummets at AD failure; Keytruda has much upside in China, analysts say; Korea Exchange is dragged into Samsung accounting probe.

Dr. Reddy's recalls more meds in the U.S., while the EMA recanted its plant's GMP certificate; China approved a domestic Ebola vaccine.

China's FDA approved a domestically developed Ebola vaccine based on a different virus type from GSK's and Merck's shots.